

NRG Principal Investigators and Research Associates are cordially invited to a kick-off meeting to discuss

NRG-LU003: A Biomarker-Driven Protocol for Previously Treated ALK-Positive NSCLC Patients: The NCI-NRG ALK Protocol

Date: Saturday, July 20, 2019

Start and End Time: 10:30am – 11:30m

Learning Objectives:

Following this activity, participants will be better able to:

1. Discuss the significance of the study.
2. Apply standards and procedures required to participate in the trial.
3. Discuss the requirements for pathology review.
4. Overview of statistical design and treatment assignment.

Agenda

Welcome and Introductions – *Erica Field, NRG Oncology*

Protocol Overview – *Shakun Malik, MD, NRG-LU003 Co-Chairs*

Blood Assay and Tissue Analysis – *Lynn Sullivan, Foundation of Medicine*

Statistical Design – *Chen Hu, PhD, Statistician, NRG Oncology*

Registration and Data Entry – *Jeff Serianni and Amy Krystkiewicz, Data Management, NRG Oncology*

Question and Answer Session